The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contributing mutations and their phenotypic characteristics including progression to the metastatic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detection and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics &Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Initially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and hands-on execution of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targeting modalities. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potential therapies, and spurs collaborations between Kl engineers and scientists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including additional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfectly with the NCI's desire to advance translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-42
Application #
8466727
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
42
Fiscal Year
2013
Total Cost
$124,711
Indirect Cost
$88,839
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
McConnell, Russell E; Edward van Veen, J; Vidaki, Marina et al. (2016) A requirement for filopodia extension toward Slit during Robo-mediated axon repulsion. J Cell Biol 213:261-74
Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16
Yin, Hao; Bogorad, Roman L; Barnes, Carmen et al. (2016) RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol 64:899-907
Hosios, Aaron M; Hecht, Vivian C; Danai, Laura V et al. (2016) Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev Cell 36:540-9
Jhunjhunwala, Siddharth; Alvarez, David; Aresta-DaSilva, Stephanie et al. (2016) Frontline Science: Splenic progenitors aid in maintaining high neutrophil numbers at sites of sterile chronic inflammation. J Leukoc Biol 100:253-60
Tirosh, Itay; Izar, Benjamin; Prakadan, Sanjay M et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352:189-96
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167
Sun, Daphne; Dalin, Simona; Hemann, Michael T et al. (2016) Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep 6:36198
Kimmerling, Robert J; Lee Szeto, Gregory; Li, Jennifer W et al. (2016) A microfluidic platform enabling single-cell RNA-seq of multigenerational lineages. Nat Commun 7:10220
Lowther, Daniel E; Goods, Brittany A; Lucca, Liliana E et al. (2016) PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 1:

Showing the most recent 10 out of 673 publications